The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Subscribe To Our Newsletter & Stay Updated
